Medrogestone (M) is a derivative of 17 methylprogesterone (P) used for P insufficiency at oral doses of 5 to 15 mg/day (D). We studied the ability of M to inhibit cyclic pituitary-ovarian activity when given at a dose of 10 mg/d from D4 to D24. Ten healthy Caucasian females, aged from 21 to 33, volunteered for an open 2 consecutive cycle study (cycle 1 = control, cycle 2 = M). At inclusion mean (+/- SD) cycle length was 28.6 +/- 1.9 D. Plasma LH, FSH, E2, P, were measured daily from D10 to D20 and at D22, 24, 26. During cycle 1, every subject showed an ovulatory pattern with mid cycle E2 peak (151-400 pg/ml), LH peak (12-59 mUI/ml) and luteal P rise (9.4-22.8 ng/ml). Under M ovulatory surges were suppressed in each of the 10 subjects and P remained below 0.8 ng/ml. These data show that in addition to its known progestomimetic effect, M is a potent ovulation inhibitor when given from D4 to D24 of the cycle.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of White Noise Intervention on Sleep Quality and Immunological Indicators of Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Noise Health
January 2025
Department of Geriatric Health Internal Medicine, Qingdao Municipal Hospital, Qingdao 266000, China.
Objective: Evaluate the effect of white noise intervention on sleep quality and immunological indicators of patients with breast cancer undergoing neoadjuvant chemotherapy (NAC).
Methods: From January 2020 to December 2022, 104 newly diagnosed female patients (the number of people who met the inclusion criteria) with breast cancer who were confirmed to be preoperative NAC by puncture pathology were selected for a randomised single-blind trial. The patients were randomly divided into an observation group and a control group, with 52 cases in each group.
Background: Emergency department (ED) encounters are often the only healthcare provider encounter for patients seeking care after a reported sexual assault (SA), making the encounter a crucial opportunity to connect patients to support services in the community. An opportunity existed at an urban Level II trauma center to standardize SA discharge planning.
Aims: This quality improvement project aimed to improve access to SA support services.
Realizing an Energy-Dense Potassium Metal Battery at -40 °C via an Integrated Anode-Free and Dual-Ion Strategy.
J Am Chem Soc
January 2025
School of Chemistry, Key Laboratory of Bio-Inspired Smart Interfacial Science and Technology of Ministry of Education, Beihang University, Beijing 100191, China.
Potassium (K)-based batteries hold great promise for cryogenic applications owing to the small Stokes radius and weak Lewis acidity of K. Nevertheless, energy-dense (>200 W h kg) K batteries under subzero conditions have seldom been reported. Here, an over 400 W h kg K battery is realized at -40 °C via an anode-free and dual-ion strategy, surpassing these state-of-the-art K batteries and even most Li/Na batteries at low temperatures (LTs).
View Article and Find Full Text PDFTargeted Next-Generation Sequencing in Succinate Dehydrogenase-Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway.
JCO Precis Oncol
January 2025
Sarcoma Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Purpose: Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to unique clinical features. Advanced SDH-deficient GISTs are usually treated with the same therapies targeting KIT and PDGFRA receptors as those used in metastatic GIST. However, these treatments display less activity in the absence of alternative therapeutic options.
View Article and Find Full Text PDFTrastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
J Clin Oncol
January 2025
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.
Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!